Efficacy and Safety of a Booster Regimen of Ad26.COV2.S Vaccine against Covid-19
Karin Hardt, An Vandebosch, Jerry Sadoff, Mathieu Le Gars, Carla Truyers, David Lowson, Ilse Van Dromme, Johan Vingerhoets, Tobias Kamphuis, Gert Scheper, Javier Ruiz-Guiñazú, Saul N. Faust, Christoph D. Spinner, Hanneke Schuitemaker, Johan Van Hoof, Macaya Douoguih, Frank Struyf, the ENSEMBLE2 Study Group
doi: https://doi.org/10.1101/2022.01.28.22270043
Karin Hardt
1Janssen Research and Development, Beerse, Belgium
Ph.D.An Vandebosch
1Janssen Research and Development, Beerse, Belgium
Ph.D.Jerry Sadoff
2Janssen Vaccines and Prevention, Leiden, The Netherlands
M.D.Mathieu Le Gars
2Janssen Vaccines and Prevention, Leiden, The Netherlands
Ph.D.Carla Truyers
1Janssen Research and Development, Beerse, Belgium
Ph.D.David Lowson
3Janssen Research and Development, High Wycombe, UK
M.Sc.Ilse Van Dromme
1Janssen Research and Development, Beerse, Belgium
Ph.D.Johan Vingerhoets
1Janssen Research and Development, Beerse, Belgium
Ph.D.Tobias Kamphuis
2Janssen Vaccines and Prevention, Leiden, The Netherlands
Ph.D.Gert Scheper
2Janssen Vaccines and Prevention, Leiden, The Netherlands
Ph.D.Javier Ruiz-Guiñazú
1Janssen Research and Development, Beerse, Belgium
M.D.Saul N. Faust
4NIHR Southampton Clinical Research Facility and Biomedical Research Centre, Southampton, UK; Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK
F.R.C.P.C.H.Christoph D. Spinner
5Technical University of Munich, Munich, Germany
M.D.Hanneke Schuitemaker
2Janssen Vaccines and Prevention, Leiden, The Netherlands
Ph.D.Johan Van Hoof
2Janssen Vaccines and Prevention, Leiden, The Netherlands
M.D.Macaya Douoguih
2Janssen Vaccines and Prevention, Leiden, The Netherlands
M.D.Frank Struyf
1Janssen Research and Development, Beerse, Belgium
M.D.Data Availability
The data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at https://www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at http://yoda.yale.edu.
Posted January 31, 2022.
Efficacy and Safety of a Booster Regimen of Ad26.COV2.S Vaccine against Covid-19
Karin Hardt, An Vandebosch, Jerry Sadoff, Mathieu Le Gars, Carla Truyers, David Lowson, Ilse Van Dromme, Johan Vingerhoets, Tobias Kamphuis, Gert Scheper, Javier Ruiz-Guiñazú, Saul N. Faust, Christoph D. Spinner, Hanneke Schuitemaker, Johan Van Hoof, Macaya Douoguih, Frank Struyf, the ENSEMBLE2 Study Group
medRxiv 2022.01.28.22270043; doi: https://doi.org/10.1101/2022.01.28.22270043
Efficacy and Safety of a Booster Regimen of Ad26.COV2.S Vaccine against Covid-19
Karin Hardt, An Vandebosch, Jerry Sadoff, Mathieu Le Gars, Carla Truyers, David Lowson, Ilse Van Dromme, Johan Vingerhoets, Tobias Kamphuis, Gert Scheper, Javier Ruiz-Guiñazú, Saul N. Faust, Christoph D. Spinner, Hanneke Schuitemaker, Johan Van Hoof, Macaya Douoguih, Frank Struyf, the ENSEMBLE2 Study Group
medRxiv 2022.01.28.22270043; doi: https://doi.org/10.1101/2022.01.28.22270043
Subject Area
Subject Areas
- Addiction Medicine (396)
- Allergy and Immunology (708)
- Anesthesia (199)
- Cardiovascular Medicine (2909)
- Dermatology (249)
- Emergency Medicine (437)
- Epidemiology (12683)
- Forensic Medicine (10)
- Gastroenterology (824)
- Genetic and Genomic Medicine (4542)
- Geriatric Medicine (413)
- Health Economics (723)
- Health Informatics (2898)
- Health Policy (1066)
- Hematology (383)
- HIV/AIDS (919)
- Medical Education (422)
- Medical Ethics (115)
- Nephrology (466)
- Neurology (4305)
- Nursing (233)
- Nutrition (633)
- Oncology (2251)
- Ophthalmology (640)
- Orthopedics (258)
- Otolaryngology (324)
- Pain Medicine (276)
- Palliative Medicine (83)
- Pathology (496)
- Pediatrics (1192)
- Primary Care Research (492)
- Public and Global Health (6889)
- Radiology and Imaging (1518)
- Respiratory Medicine (912)
- Rheumatology (433)
- Sports Medicine (381)
- Surgery (482)
- Toxicology (60)
- Transplantation (208)
- Urology (178)